Results 11 to 20 of about 96 (70)

Characteristics of adverse reactions of three anti-glioma drugs in WHO-VigiAccess

Frontiers in Pharmacology
IntroductionAntitumor medications such as Avastin, Berubicin, and Temozolomide have fundamentally transformed the treatment landscape for gliomas by exhibiting potent pharmacological effects on both high-grade and low-grade gliomas.
Huadong Ke, Zicheng Zhang, Zhao Yu, Baiquan Zhang, Rui Chen, Qiang Zhou, Qian Guo, Xiaohui Lou   +7 more
exaly   +3 more sources

Adverse events of hepatic anti-fibrotic agents in phase 3 and above clinical trials: a descriptive analysis of the WHO-VigiAccess database

Frontiers in Pharmacology
IntroductionLiver fibrosis is a pathological condition in response to chronic liver injuries. Currently, there is no Food and Drug Administration (FDA) approved pharmacotherapy for liver fibrosis.
Yuwei Liu
exaly   +3 more sources

Adverse Reactions of First-Line Tyrosine Kinase Inhibitors in Advanced Hepatocellular Carcinoma Treatment: A Descriptive Analysis From WHO-VigiAccess

International Journal of Hepatology
Conclusion: While gastrointestinal toxicities were class-wide concerns, agent-specific risks necessitate tailored monitoring. These findings emphasized the need for vigilant monitoring and personalized management in clinical practice.
Wei fan Sui, Yu xin Duan, Ze feng Cai, Yi mao Xia, Jian yun Li, Jian hua Fu   +5 more
doaj   +2 more sources

Assessing the real-world safety of fenofibric acid for hyperlipidemia: results from WHO-VigiAccess and FAERS databases

Frontiers in Medicine
BackgroundFenofibric acid is a small-molecule fibrate that functions as an agonist of peroxisome proliferator-activated receptor alpha (PPARα) and serves as an inhibitor of liver fatty acid-binding protein.
Yaxing Li, Yaxing Li, Yi Wang, Jidang Zhang, Ruonan Zhang, Zhiwen Yao, Zhiwen Yao, Xuepin Chen, Xingli Xu   +8 more
exaly   +3 more sources

Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration’s adverse event reporting system databases

Frontiers in Pharmacology
BackgroundThis study aimed to investigate the real-world profile of adverse events (AEs) associated with gepant medications in the clinical treatment of migraines by analyzing data collected from the VigiAccess database and the U.S.
Huang Yushen
exaly   +3 more sources

A real-world data analysis of ocular adverse events linked to anti-VEGF drugs: a WHO-VigiAccess study

Frontiers in Pharmacology
IntroductionVascular endothelial growth factor (VEGF) is key to wet age-related macular degeneration (wAMD). Anti-VEGF drugs are the main treatment in clinics.
Chen Li, Yicheng Lu, Ziyue Song, Yueqi Liu   +3 more
exaly   +3 more sources

Adverse reactions of four multi-targeted tyrosine kinase inhibitors: a descriptive analysis of the WHO-VigiAccess database

Frontiers in Pharmacology
BackgroundThe introduction of multi-targeted tyrosine kinase inhibitors (MTKIs) such as axitinib, lenvatinib, sorafenib, and sunitinib has greatly broadened the available treatment options for Renal Cell Carcinoma (RCC).
Lijun Li, Lijun Li, Lijun Li, Jiayu Bai, Xuelong Wen, Xuefan Zeng   +5 more
exaly   +3 more sources

Adverse event profile of five anti head and neck squamous cell carcinoma drugs: a descriptive analysis from WHO-VigiAccess

Frontiers in Pharmacology
BackgroundHead and neck squamous cell carcinoma (HNSCC) remains a significant global health concern, with treatment outcomes for advanced or metastatic stages being suboptimal despite the availability of various targeted therapies and immunotherapies ...
Weimin Gao, Zhigang Xia, Tingfeng Zhou, Youlin Dong   +3 more
exaly   +3 more sources

Adverse event profile of lomustine and temozolomide: a descriptive analysis from WHO-VigiAccess

Frontiers in Pharmacology
IntroductionIn gliomas, various oncogenic factors can lead to an imbalance between cell proliferation and apoptosis. Lomustine inhibits tumor cell growth by disrupting DNA replication and repair mechanisms.
Hua Luo, Liwei Zhang, Luo Hua
exaly   +3 more sources

A severe case of rhabdomyolysis after Moderna mRNA anti‐COVID‐19 vaccine with a literature review

Clinical Case Reports, Volume 11, Issue 5, May 2023., 2023
The identification of rhabdomyolysis as a potential fatal adverse reaction to recent COVID‐19 vaccines is essential. As the symptoms of rhabdomyolysis are not specific, the threshold to actively search for this complication should be low. Abstract The identification of rhabdomyolysis as a potential fatal adverse reaction to recent COVID‐19 vaccines is ...
Maria Sheka, Yann Coattrenec, Kuntheavy Ing Lorenzini, Mathieu Nendaz   +3 more
wiley   +1 more source